000			02045 a2200613 4500
005			20250518011030.0
264		0	_c20190221
008			201902s 0 0 eng d
022			_a1095-6859
024	7		_a10.1016/j.ygyno.2018.11.008 _2doi
040			_aNLM _beng _cNLM
100	1		_aHeitz, F
245	0	0	_aEarly tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. _h[electronic resource]
260			_bGynecologic oncology _c02 2019
300			_a235-242 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aCarboplatin _xadministration & dosage
650	0	4	_aCarcinoma, Ovarian Epithelial _xdrug therapy
650	0	4	_aDouble-Blind Method
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aIndoles _xadministration & dosage
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Staging
650	0	4	_aNeoplasm, Residual _xpathology
650	0	4	_aPaclitaxel _xadministration & dosage
650	0	4	_aPrognosis
650	0	4	_aYoung Adult
700	1		_aHarter, P
700	1		_aÅvall-Lundqvist, E
700	1		_aReuss, A
700	1		_aPautier, P
700	1		_aCormio, G
700	1		_aColombo, N
700	1		_aReinthaller, A
700	1		_aVergote, I
700	1		_aPoveda, A
700	1		_aOttevanger, P B
700	1		_aHanker, L C
700	1		_aLeminen, A
700	1		_aAlexandre, J
700	1		_aCanzler, U
700	1		_aSehouli, J
700	1		_aHerrstedt, J
700	1		_aFiane, B
700	1		_aMerger, M
700	1		_adu Bois, A
773	0		_tGynecologic oncology _gvol. 152 _gno. 2 _gp. 235-242
856	4	0	_uhttps://doi.org/10.1016/j.ygyno.2018.11.008 _zAvailable from publisher's website
999			_c29081326 _d29081326